Anti-Infectives · LP-034
Cloxacillin Capsules
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-034Anti-Infectives
- Generic identity
- CloxacillinCapsule
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-034
- Generic identity
- Cloxacillin
- Presentation
- Capsule
- Catalogue strength
- 250 mg; 500 mg
- Catalogue pack
- Blister 10 x 10 capsules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cloxacillin.
- Dosage form: capsule.
- Proposed strengths: 250 mg and 500 mg.
- General catalogue pack: blister 10 × 10 capsules.
Layer 02 · Unresolved product-specific fields
- Exact cloxacillin salt/hydrate and strength basis, capsule shell/fill composition.
- Strength-to-pack/SKU mapping and whether capsule properties differ by strength.
- Approved indications, administration instructions and allergy/safety labelling for the intended jurisdiction.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 250 mg | Capsule | — | Catalogue pack: blister 10 × 10 capsules; strength-specific mapping not supplied | Exact chemical basis, capsule composition and SKU evidence required. |
| B | 500 mg | Capsule | — | Catalogue pack: blister 10 × 10 capsules; strength-specific mapping not supplied | Exact chemical basis, capsule composition and SKU evidence required. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cloxacillin is a penicillin antibiotic used for selected infections involving susceptible bacteria, particularly some staphylococci. Resistance patterns and the exact diagnosis determine whether it is appropriate. It should not be described as an antibiotic that covers every resistant organism. This educational summary is limited to ingredient background; the cited reference monograph and the approved local label are needed to establish any Luang Pharma product indication.
Clinical context and therapeutic role
Professional selection should be based on the likely organism, infection site, disease severity and local resistance guidance. The distinction between susceptible staphylococci and methicillin-resistant organisms is important. Some infections require microbiology, drainage or hospital care rather than an oral product alone. The prescriber should review previous beta-lactam reactions, renal and hepatic disease and concomitant medicines, then define a follow-up plan appropriate to the particular infection.
Selected safety context
Penicillin allergy can produce a serious reaction, including breathing difficulty or facial swelling. Gastrointestinal upset and diarrhoea can occur, while severe persistent or bloody diarrhoea needs assessment. Rash, jaundice or unusual bruising should also be reviewed. A previous serious reaction to any beta-lactam requires careful evaluation. The current locally approved prescribing information must be consulted for contraindications, interactions and monitoring; the reference manufacturer’s label does not establish authorization for another product.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes an oral capsule. Capsule shell, fill composition and release behavior are product-specific and are not established by the ingredient name. Opening a capsule or dispersing its contents should be considered only when the approved instructions or a pharmacist confirms that this is appropriate.
Retain the original labeled pack and check its integrity and expiry before use. Storage requirements must come from the supplied product information; no shelf life or temperature is inferred here. A pharmacist can advise on an alternative presentation if swallowing is difficult.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A qualified prescriber should establish the infection and need for treatment, consult current local guidance and resistance information where relevant, and select a suitable route. Generic reference literature is not a substitute for the authorized local product information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07b checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| Health Canada: JAMP Cloxacillin product monographArchived source classification: Canadian regulator-hosted product monograph | Source revision recorded: Prepared 6 January 2021; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-034.
Professional enquiries
Request product-specific evidence for LP-034.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.